{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T08:47:07Z","timestamp":1782463627285,"version":"3.54.5"},"reference-count":40,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["ACR Open Rheumatology"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the long\u2010term effects of anifrolumab on hematologic and serologic parameters over four years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This analysis included 536 patients with moderate\u2010to\u2010severe systemic lupus erythematosus (SLE) who received intravenous anifrolumab 300 mg (n\u00a0=\u00a0358) or placebo (n\u00a0=\u00a0178) in the 52\u2010week, phase 3 TULIP\u20101\/2 trials (NCT02446912 and NCT02446899) and continued the same treatment in the 3\u2010year, long\u2010term extension (LTE, NCT02794285), or would have done if not discontinued early; 369 patients entered the LTE. Changes from baseline to week 208 in lymphocytes, hemoglobin, platelets, neutrophils, complement C3, C4, anti\u2013double\u2010stranded DNA (dsDNA), and Igs were analyzed descriptively. British Isles Lupus Assessment Group\u2013based Composite Lupus Assessment (BICLA) response at week 52 was analyzed by treatment and lymphocyte, hemoglobin, and platelet normalization in responders versus nonresponders, regardless of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Numerically greater improvements from baseline in lymphocyte, hemoglobin, platelet, and neutrophil levels were observed with anifrolumab over placebo. Comparing anifrolumab versus placebo, lymphocyte and hemoglobin normalization rates were higher and platelet normalization was comparable. BICLA response was associated with lymphocyte, hemoglobin, and platelet normalization over four years, regardless of treatment. Conversely, BICLA responses were higher with anifrolumab versus placebo, irrespective of baseline lymphocyte, hemoglobin, and platelet levels. Improvements in anti\u2010dsDNA, C3, C4, and Igs from baseline were greater with anifrolumab versus placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The normalization of hematologic parameters and sustained improvements in serologic markers support the long\u2010term efficacy of anifrolumab in patients with moderate\u2010to\u2010severe SLE. Clinical response to anifrolumab was associated with improvements in biomarkers, suggesting restoration of overall immune health.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr2.90065","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:05:16Z","timestamp":1781532316000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long\u2010Term Anifrolumab Treatment Normalizes Hematologic Parameters and Several Serologic Markers in Patients With Systemic Lupus Erythematosus"],"prefix":"10.1002","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-4755","authenticated-orcid":false,"given":"Edward M.","family":"Vital","sequence":"first","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health University of Leeds  Leeds United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahir","family":"Amoura","sequence":"additional","affiliation":[{"name":"French National Reference Center for Systemic Lupus Erythematosus H\u00f4pital La Piti\u00e9\u2010Salp\u00eatri\u00e8re, Sorbonne University  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Kalunian","sequence":"additional","affiliation":[{"name":"School of Medicine University of California  San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian N.","family":"Bruce","sequence":"additional","affiliation":[{"name":"Centre for Musculoskeletal Research The University of Manchester  Manchester United Kingdom"},{"name":"Centre for Public Health, Faculty of Medicine, Health and Life Sciences Queen's University Belfast  Belfast United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine University of Occupational and Environmental Health Japan  Kitakyushu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Manzi","sequence":"additional","affiliation":[{"name":"Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network  Pittsburgh Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihor","family":"Hupka","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Research and Development AstraZeneca  Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Knagenhjelm","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Research and Development AstraZeneca  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Al\u2010Mossawi","sequence":"additional","affiliation":[{"name":"St Edmund Hall, University of Oxford  Oxford United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina","family":"Lindholm","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Research and Development AstraZeneca  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"e_1_2_8_2_1","article-title":"A practical perspective of the hematologic manifestations of systemic lupus erythematosus","volume":"14","author":"Santacruz JC","year":"2022","journal-title":"Cureus"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213386"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34473"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22224"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.3109\/09537101003735564"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab217"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.05.009"},{"key":"e_1_2_8_9_1","first-page":"459","article-title":"Isolated neutropenia in systemic lupus erythematosus","volume":"50","author":"Alhammadi NA","year":"2023","journal-title":"J Rheumatol"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011356"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.186"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000815"},{"key":"e_1_2_8_13_1","first-page":"11","article-title":"Clinical and immunological biomarkers for systemic lupus erythematosus","author":"Yu H","year":"2021","journal-title":"Biomolecules"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874312901307010087"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2020.10.014"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1878-y"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21031"},{"key":"e_1_2_8_18_1","unstructured":"SAPHNELO (anifrolumab\u2010fnia) [Prescribing Information].2024. Accessed May 15 2026.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761123s005lbl.pdf"},{"key":"e_1_2_8_19_1","unstructured":"AstraZeneca.Saphnelo approved in the EU for the treatment of moderate to severe systemic lupus erythematosus.2022. Accessed May 15 2026.https:\/\/www.astrazeneca.com\/media\u2010centre\/press\u2010releases\/2022\/saphnelo\u2010approved\u2010in\u2010eu\u2010for\u2010sle.html"},{"key":"e_1_2_8_20_1","unstructured":"AstraZeneca.Saphnelo approved in Japan for systemic lupus erythematosus.2021. Accessed May 15 2026.https:\/\/www.astrazeneca.com\/media\u2010centre\/press\u2010releases\/2021\/saphnelo\u2010approved\u2010in\u2010japan\u2010for\u2010sle.html"},{"key":"e_1_2_8_21_1","article-title":"SAPHNELO\u2122 anifrolumab for injection","author":"AstraZeneca Canada inc","year":"2021","journal-title":"Product monograph."},{"key":"e_1_2_8_22_1","article-title":"SAPHNELO\u00ae(anifrolumab) concentrated solution for infusion","author":"AstraZeneca pty ltd MPN","year":"2022","journal-title":"Australian product information."},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42392"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30076-1"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41598"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39962"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000286"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2023-eular.1534"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400928"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22312-y"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00993-3"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41518"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-101921-042422"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225445"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19124090"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.932388"},{"key":"e_1_2_8_39_1","first-page":"73","article-title":"Efficacy of anifrolumab in serological subgroups of patients with SLE participating in 2 phase 3 trials [abstract]","author":"Bruce IN","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000261"},{"key":"e_1_2_8_41_1","first-page":"A169","article-title":"LBO1 DORIS remission in patients with SLE treated with anifrolumab or placebo during the 4\u2010year TULIP\u2010LTE trial: post hoc analysis","volume":"11","author":"Vollenhoven Rv","year":"2024","journal-title":"Lupus Sci Med"}],"container-title":["ACR Open Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.90065","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr2.90065","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.90065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T08:04:10Z","timestamp":1782461050000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr2.90065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/acr2.90065"],"URL":"https:\/\/doi.org\/10.1002\/acr2.90065","archive":["Portico"],"relation":{},"ISSN":["2578-5745","2578-5745"],"issn-type":[{"value":"2578-5745","type":"print"},{"value":"2578-5745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2025-07-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e90065"}}